VOTRIENT (GlaxoSmithKline LLC)
Welcome to the PulseAid listing for the VOTRIENT drug offered from GlaxoSmithKline LLC. This Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Cytochrome P450 2C8 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | GlaxoSmithKline LLC |
| NON-PROPRIETARY NAME: | pazopanib hydrochloride |
| SUBSTANCE NAME: | PAZOPANIB HYDROCHLORIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Cytochrome P450 2C8 Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2009-10-19 |
| END MARKETING DATE: | 2017-11-30 |
VOTRIENT HUMAN PRESCRIPTION DRUG Details:
| Item Description | VOTRIENT from GlaxoSmithKline LLC |
| LABELER NAME: | GlaxoSmithKline LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 200(mg/1) |
| START MARKETING DATE: | 2009-10-19 |
| END MARKETING DATE: | 2017-11-30 |
| PRODUCT ID: | 0173-0804_7cc70c3d-7852-4de5-a116-194017e95017 |
| PRODUCT NDC: | 0173-0804 |
| APPLICATION NUMBER: | NDA022465 |
Other PAZOPANIB HYDROCHLORIDE Pharmaceutical Manufacturers / Labelers:
